Zucara Therapeutics is developing the first once-daily therapeutic to prevent hypoglycemia (low blood sugar) in patients with diabetes. This pre-clinical technology is directed at regulating a hormone in the pancreas called somatostatin which in Type 1 diabetes is not properly controlled. It has demonstrated potential to specifically blocksomatostatin type 2 receptors in the pancreas thereby preventing hypoglycemia and restoring natural glucose levels in the blood. Zucara’s method offers a clear advantage to patients as a preventative measure whereas current drug therapies can only rescue a patient already experiencing potentially dangerous low blood sugar.

Biotechnology

Health Care

Pharmaceutical

Zucara Therapeutics Inc.

Michael Midmer

Ginger Vieira

Richard Liggins

This department oversees the management and coordination of chemistry, manufacturing, controls, and scientific program activities.

CMC and Scientific Operations

This department oversees strategic direction and governance at the highest organizational level.

Zucara Therapeutics Inc.

Org chart

Teams

CMC and Scientific Operations

Executive Leadership

Offices

Zucara Therapeutics Inc.

Org chart

Teams

CMC and Scientific Operations

Executive Leadership

Offices

Related companies